PriceTargets.com logo

Imunon - IMNN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 757.14%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.40 As of 05/17/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for IMNN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Imunon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMNN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMNN

Analyst Price Target is $12.00
▲ +757.14% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Imunon in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 757.14% upside from the last price of $1.40.

This chart shows the closing price for IMNN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Imunon. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2024HC WainwrightLower TargetBuy ➝ Buy$13.00 ➝ $12.00Low
4/1/2024HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $13.00Low
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
9/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
5/12/2023HC WainwrightReiterated RatingBuyLow
11/14/2022Brookline Capital ManagementReiterated RatingBuyLow
10/13/2022Alliance Global PartnersInitiated CoverageBuy$15.00Low
10/3/2022Brookline Capital ManagementReiterated RatingBuyLow
(Data available from 5/19/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 0 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024

Current Sentiment

  • 0 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Imunon logo
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Read More

Today's Range

Now: $1.40
Low: $1.39
High: $1.45

50 Day Range

MA: $1.29
Low: $0.79
High: $1.93

52 Week Range

Now: $1.40
Low: $0.48
High: $2.00

Volume

16,384 shs

Average Volume

47,074 shs

Market Capitalization

$13.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Imunon?

The following Wall Street analysts have issued stock ratings on Imunon in the last twelve months: HC Wainwright.
View the latest analyst ratings for IMNN.

What is the current price target for Imunon?

1 Wall Street analysts have set twelve-month price targets for Imunon in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 757.1%. HC Wainwright has the highest price target set, predicting IMNN will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Imunon in the next year.
View the latest price targets for IMNN.

What is the current consensus analyst rating for Imunon?

Imunon currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMNN will outperform the market and that investors should add to their positions of Imunon.
View the latest ratings for IMNN.

What other companies compete with Imunon?

Other companies that are similar to Imunon include Eterna Therapeutics, Kiora Pharmaceuticals, Purple Biotech, RedHill Biopharma and Akari Therapeutics. Learn More about companies similar to Imunon.

How do I contact Imunon's investor relations team?

Imunon's physical mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The company's listed phone number is (609) 896-9100 and its investor relations email address is [email protected]. The official website for Imunon is www.imunon.com. Learn More about contacing Imunon investor relations.